OSE Immunotherapeutics
http://ose-immuno.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OSE Immunotherapeutics
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Alexion On Its AstraZeneca Integration And Growth Plan
Two years after being acquired by AstraZeneca, the company remains relatively autonomous in rare disease, but with “bridges” to its big pharma parent.
Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
OSE On The Up As Phase III For Cancer Vaccine Is Prepped
OSE’s late-stage ambitions for Tedopi were stalled by the pandemic but the Nantes-based firm has now requested a meeting with the US FDA to get the Phase III program for the anticancer vaccine back on track.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Biotech Synergy
- Effimune SA
- Orphan Synergy Europe Pharma
- OSE Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice